Merck Returns Rights for Safinamide to Newron
Darmstadt, Germany, October 21, 2011 – Merck KGaA announced today that it has decided to return all rights for safinamide to Newron Pharmaceuticals S.p.A. Merck had acquired exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson’s disease and other therapeutic applications, pursuant to its agreement with Newron signed in 2006.
The termination of this agreement will become effective in April 2012 and will result in approximately €40 million of additional costs for the Merck Serono division in the fourth quarter of 2011. These costs will be excluded from both the division’s and the Merck Group’s fourth quarter underlying core operating result.
Merck’s decision was made as part of the ongoing review and re-prioritization of its R&D pipeline. In Merck’s view, safinamide has a more limited market potential than originally anticipated. The book value of safinamide was initially written-down in Merck’s Q4 2010 financial statements and its remaining book value was fully written-off during the second quarter of 2011.
Merck will meet its contractual and ethical commitments regarding the ongoing clinical development program for safinamide. Merck will work with Newron to execute an appropriate transfer of the program to Newron. The collaboration of Merck and Newron on pruvanserin and sarizotan continues.
Safinamide is an alpha-aminoamide that is currently being developed as an add-on therapy to dopamine agonists or to levodopa in patients with early or mid- to late-stage Parkinson’s disease (PD). It is believed to have both dopaminergic and non-dopaminergic activities, including selective and reversible inhibition of monoamine oxidase B (MAO-B), activity-dependent sodium channel antagonism and inhibition of glutamate release in vitro. Studies are ongoing to better understand safinamide’s actions in patients with PD.
Safinamide is currently in Phase III for PD and its clinical program includes:
- The ongoing MOTION (safinaMide add-On To dopamine agonists for early Idiopathic ParkinsON’s) study: a phase III, double-blind, placebo-controlled randomized six-month trial to evaluate efficacy and safety of two doses of safinamide (50mg/day or 100 mg/day), as add-on to dopamine agonist therapy versus dopamine agonist therapy alone, in early stage PD patients and the MOTION extension 18-month phase III, double-blind, placebo-controlled extension study designed to provide data on the long-term safety and efficacy.
- The ongoing SETTLE (SafinamidE Treatment as add-on To LEvodopa) study: a Phase III, double-blind, placebo-controlled six-month trial to evaluate efficacy and safety of a dose range of safinamide (50-100 mg/day) as add-on to levodopa therapy versus levodopa therapy alone, in mid- to late-stage PD patients.
- The completed 015 study: a phase III, double-blind, placebo-controlled six-month study to evaluate efficacy and safety of a low (50-100mg/day) and high (150-200mg/day) dose range of safinamide as add-on to dopamine agonist therapy versus dopamine agonist therapy alone in early stage PD patients.
- The completed 017 study (the 015 extension study): a phase III, double blind, placebo-controlled, 12-month extension study to evaluate the long-term efficacy and safety of a dose range of safinamide of 50-200mg/day, as add-on to dopamine agonist therapy versus dopamine agonist therapy alone in early stage PD patients
- The completed 016 study: a phase III, double-blind, placebo-controlled randomized six-month trial to evaluate efficacy and safety of two doses safinamide (50mg/day or 100mg/day) as add-on to levodopa therapy versus levodopa therapy alone, in patients with mid- to late-stage PD experiencing motor fluctuations.
- The completed 018 study (the 016 extension study): a phase III, double-blind, randomized, placebo-controlled,18-month extension to Study 016, to evaluate the long-term efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, compared with placebo, as add-on treatment to levodopa therapy in patients with mid- to late-stage PD experiencing motor fluctuations.
Parkinson's disease is a degenerative disorder of the central nervous system that often impairs the patient’s motor skills and speech. Parkinson's disease belongs to a group of conditions called movement disorders. It is characterized by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement (akinesia). The primary symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Secondary symptoms may include high-level cognitive dysfunction and subtle language problems. Parkinson’s disease is both chronic and progressive. It is estimated that more than 3 million people in the industrialized countries suffer from Parkinson’s disease.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website www.merckgroup.com/media. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 40,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2014, Merck generated sales of € 11.3 billion in 66 countries.
Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.